SEC Filing Summary: Niagen Bioscience, Inc. (NAGE)
Business Context and Reporting Period
This Form 8-K was filed on August 6, 2025, by Niagen Bioscience, Inc., a Delaware corporation trading on the Nasdaq Capital Market. The filing serves to announce the Company's earnings results for the quarter ended June 30, 2025, and to disclose a corporate presentation made available on the Company's website.
Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) and earnings presentation (Exhibit 99.2), which are not included in the source text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. No specific material changes in financial condition or operations are quantified within this document.
Guidance, Outlook, and Risks
The Company released a corporate presentation (Exhibit 99.2) which may contain management commentary, outlook, or guidance, but the content of this presentation is not included in the filing text. The filing explicitly states that the information furnished in Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of that section.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the quarter ended June 30, 2025, by reviewing the attached Press Release (Exhibit 99.1).
- Review the Earnings Presentation (Exhibit 99.2) for management's forward-looking statements, guidance, and strategic outlook.
- Confirm the Company's liquidity position and debt obligations as detailed in the full financial statements referenced in the exhibits.
- Note that the information in this 8-K is furnished and not "filed" under Section 18 of the Exchange Act, limiting the legal liability associated with the disclosures in this specific document.